Although the benefits of originator infliximab have been deemed to outweigh the potential harm during pregnancy, in a recent observational study, researchers looked to evaluate whether biosimilar infliximab therapy was associated with any new safety risks.
Anti-tumor necrosis factor (anti-TNF) therapy used to treat pregnant patients with inflammatory bowel disease (IBD) has been linked with lower birth weight, shorter gestational term, and in some studies, more frequent birth defects or spontaneous abortion.
Although the benefits of originator infliximab have been deemed to outweigh the potential harm during pregnancy, in a recent observational study, researchers looked to evaluate whether biosimilar infliximab therapy was associated with any new safety risks in the same population.
The observational study was conducted among 20 pregnant women who were treated with biosimilar infliximab. Researchers compiled data on disease activity, prior treatment, and newborn outcome, as well as blood levels of the anti-TNF agent.
Of the 20 women studied, 16 had Crohn disease, and 4 had ulcerative colitis. Patients’ mean age was 28.7 (±4.1), and 55% (n = 11) were pregnant for the first time.
At the time they conceived, 30% (6) of the patients had active disease, and 65% (n = 13) were in remission. One patient was newly diagnosed with acute severe colitis after having conceived. Other than the last patient, all women had already received infliximab treatment prior to pregnancy.
Researchers recorded 19 live births, with a mean weight 3305 g (±493 g), 18 of which were at term. One was both preterm and had a low birth weight. One pregnancy was spontaneously aborted.
In addition, researchers found that disease activity at conception was associated with both lower birth weight; mean birthweight was 3549 g (±392 g) in the remission group versus 2921 g (±390 g) in the active disease group, respectively (P =.0043).
Although researchers note that findings were limited by the small study size, no new safety concerns were found in pregnant women treated with biosimilar infliximab. In addition, according to the study authors, this was the first report of pregnancy outcomes in women treated with biosimilar infliximab.
Reference
Kolar M, Duricova D, Bortlik M, et al. Pregnancy outcomes in women with IBD treatment with biosimilar infliximab. Presented at the European Crohn's and Colitis Organisation Congress 2018 meeting, February 14-17, 2018; Vienna, Austria. Abstract P614.
ecco-ibd.eu/publications/congress-abstract-s/abstracts-2018/item/p614-pregnancy-outcomes-in-women-with-ibd-treated-with-biosimilar-infliximab.html
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.